Not a member yet? Register now and get started.

lock and key

Sign in to your account.

Account Login

Forgot your password?

Biotechnology  // Browsing posts in Biotechnology

Exact Sciences’ Cologuard the Preferred Test for Patients Refusing Colonoscopy (EXAS)

Research Question: Will Exact Sciences’ Cologuard become physician’s screening test of choice for colon cancer? Companies: ABT, BDX, BIOC, BSX, CHEK, CPHD, DGX, EXAS, FMI, GIVN, GSK, IRWD, RHHBY By: David Franklin Click here to download the report (.pdf)   Summary of Findings Exact Sciences Corp.’s (EXAS) Cologuard has high clinical value, but it is unlikely […]


Well-Received Zarxio Will Pave Way to Eventual Wide Biosimilar Adoption

Research Question: Will Sandoz’s (Novartis) Zarxio, the first biosimilar approved by the FDA, be widely adopted by the medical and managed care community and pave the way for future biosimilars? Companies: AMGN, BOM:500359, EPRS, ESRX, HSP, KOSDAQ:068270, NVS, MRK, PFE By: Linda Richards Click here to download the report (.pdf)   Summary of Findings Adoption of […]


Aug 11 2014 Biotechnology, Healthcare

Questcor’s Acthar Gel Sales Will Be Challenged by Tightened Guidelines

Research Question: Will Questcor’s growth be derailed by UnitedHealth’s, Cigna’s and Aetna’s limited reimbursement policy for Acthar Gel? Companies: AET, AMGN, CI, GILD, MNK, QCOR, RHHBY, UNH By: David Franklin Click here to download the report (.pdf)   Summary of Findings Questcor Pharmaceuticals Inc.’s (QCOR) Acthar Gel, which represents 95% of the company’s total sales, will face challenges […]


Jul 16 2014 Biotechnology, Healthcare

Aegerion’s Juxtapid Likely to See Limited Sales Improvement

Research Question: Is the leveling off of Aegerion’s Juxtapid sales permanent, or will growth return? Companies: AEGR, AMGN, ISIS, PFE, REGN, SNY By: David Franklin Click here to download the report (.pdf)   Summary of Findings Aegerion Pharmaceuticals Inc.’s (AEGR) orphan drug Juxtapid, which treats the extremely rare HoFH lipid disorder, likely will experience only a limited sales […]


Illumina Still Leads in Challenging DNA Sequencing Market (ILMN)

Research Question: How well is Illumina positioned to face DNA sequencing research funding issues, overcapacity concerns, and next-generation technology challenges? By: David Franklin Companies: DGX, ETR:QIA/QGEN, FRA:RH05,  GNOM, ILMN, LH, LIFE, PACB, PKI, SQNM Click here to download the report (.pdf)   Summary of Findings The large-scale and next-gen sequencer markets are facing short-term challenges. Funding shifts […]


Elan’s AD Drugs Hold Potential, MS Drug Tysabri Mired by Rep (PRGO)

Research Questions: Will ELND005 and bapineuzumab (bapi), Elan’s pipeline treatments for Alzheimer’s disease, receive FDA approval and become blockbusters? Also, will the availability of a blood test and a treatment for the John Cunningham virus lead to increased sales for the multiple sclerosis drug Tysabri? By: David Franklin Companies: BAX, BIIB, ELN, EPA:SAN/SNY, ETR:BAYN/BAYRY, FRX, JNJ, […]


Neurocrine’s Elagolix Eagerly Awaited (NBIX)

Research Question: If approved by the FDA, what effect will Neurocrine’s Elagolix have on current treatments for endometriosis, and will it achieve blockbuster status? By: David Franklin Companies: ABT, LON:AZN/AZN, NBIX Click here to download the report (.pdf)   Summary of Findings Neurocrine Biosciences Inc.’s (NBIX) Phase II experimental drug Elagolix, if approved by the Food and Drug […]